Hellenic Registry for Familial Hypercholesterolemia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
- 试验地点
- 2
- 主要终点
- the prevalence of Familiar Hypercholesterolaemia in Greece
研究概览
简要总结
Familial hypercholesterolemia (FH) [heterozygous (heFH) or homozygous FH (hoFH)] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.
详细描述
In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world <5% of individuals with FH are identified .
Until lately the prevalence of heFH was traditionally considered to be ~ 1:500 individuals , although clinical and genetic studies suggest that heFH affects ~ 1:200-250 individuals . Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1). Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •both genders
- •>18 years, <80 years
- •door to door enrolment
- •eligible to sign informed consent
排除标准
- •<18 years, >80 years
- •deny to sign informed consent
结局指标
主要结局
the prevalence of Familiar Hypercholesterolaemia in Greece
时间窗: 1 month
patients with FH will be screened and include in Registry
次要结局
未报告次要终点
研究者
Genovefa Kolovou, M.D., Ph.D., F.E.S.C., S.F.S.A
Cardiologist, Head of Hellenic College of Treatment of Atherosclerosis
Hellenic College of Treatment of Atherosclerosis